跳至主要内容
临床试验/EUCTR2012-003152-37-DE
EUCTR2012-003152-37-DE进行中(未招募)不适用

A randomised trial comparing efficacy and safety afterintensification with either insulin aspart once daily as add-on or changing to basal bolus treatment with insulin degludec and insulin aspart in subjects with type 2 diabetes previously treated with insulin degludec/insulin aspart twice daily - BOOST®: INTENSIFY BID

ovo Nordisk A/S0 个研究点目标入组 97 人开始时间: 2012年11月23日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
97

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • HbA1c = 7.0% measured after 26 weeks of treatment in NN5401-3941, by central laboratory analysis
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 72
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 25

排除标准

  • - Uncontrolled or untreated severe hypertension defined as systolic blood pressure = 180 mmHg and/or diastolic blood pressure = 100 mmHg
  • - Impaired liver function, defined as alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) = 2.5 times upper limit of normal
  • - Impaired renal function defined as serum-creatinine = 125 µmol/L (= 1.4 mg/dL) for males and = 110 µmol/L (= 1.3 mg/dL) for females

研究者

相似试验